These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7544214)

  • 41. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Hirakawa A; Gotoh M
    Urology; 2016 Feb; 88():149-54. PubMed ID: 26592467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reflections on alpha blockade therapy for benign prostatic hyperplasia.
    Caine M
    Br J Urol; 1995 Mar; 75(3):265-70. PubMed ID: 7537600
    [No Abstract]   [Full Text] [Related]  

  • 44. Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
    Lee YS; Lee HN; Han JY; Choo MS; Lee KS
    J Urol; 2011 Mar; 185(3):1003-9. PubMed ID: 21251673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
    Lepor H
    Prostate Suppl; 1990; 3():75-84. PubMed ID: 1689172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?
    Lee KS; Lee HW; Han DH
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):491-501. PubMed ID: 18172610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
    Athanasopoulos A; Perimenis P
    Expert Opin Pharmacother; 2005 Nov; 6(14):2429-33. PubMed ID: 16259574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benign prostatic hyperplasia and its treatment.
    Stimson JB; Fihn SD
    J Gen Intern Med; 1990; 5(2):153-65. PubMed ID: 1690275
    [No Abstract]   [Full Text] [Related]  

  • 49. Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy.
    Vouri SM; Strope SA; Olsen MA; Xian H; Schootman M
    Urology; 2018 Dec; 122():76-82. PubMed ID: 30205105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discussion 47. PubMed ID: 9732825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
    Abrams P
    Eur Urol; 1997; 32(1):39-46. PubMed ID: 9266230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.
    Schwinn DA
    BJU Int; 2001 Sep; 88 Suppl 2():27-34; discussion 49-50. PubMed ID: 11589667
    [No Abstract]   [Full Text] [Related]  

  • 54. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate disease in older men: 1. Benign hyperplasia.
    Albertsen PC
    Hosp Pract (1995); 1997 May; 32(5):61-4, 67-8, 77 passim. PubMed ID: 9153140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bladder outflow obstruction treated with phenoxybenzamine. Preliminary note.
    Abrams P; Hollister P; Lawrence J; Doyle PT; Sherwood T; Whitaker RH
    Br J Urol; 1982 Oct; 54(5):530. PubMed ID: 6184107
    [No Abstract]   [Full Text] [Related]  

  • 58. Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Int J Clin Pract; 1998 Sep; 52(6):402-7. PubMed ID: 9894377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.